641 related articles for article (PubMed ID: 31695800)
1. Theranostics in immuno-oncology using nanobody derivatives.
Lecocq Q; De Vlaeminck Y; Hanssens H; D'Huyvetter M; Raes G; Goyvaerts C; Keyaerts M; Devoogdt N; Breckpot K
Theranostics; 2019; 9(25):7772-7791. PubMed ID: 31695800
[TBL] [Abstract][Full Text] [Related]
2. Theranostic applications of antibodies in oncology.
Fleuren ED; Versleijen-Jonkers YM; Heskamp S; van Herpen CM; Oyen WJ; van der Graaf WT; Boerman OC
Mol Oncol; 2014 Jun; 8(4):799-812. PubMed ID: 24725480
[TBL] [Abstract][Full Text] [Related]
3. In vivo near-infrared fluorescence targeting of T cells: comparison of nanobodies and conventional monoclonal antibodies.
Bannas P; Well L; Lenz A; Rissiek B; Haag F; Schmid J; Hochgräfe K; Trepel M; Adam G; Ittrich H; Koch-Nolte F
Contrast Media Mol Imaging; 2014; 9(2):135-42. PubMed ID: 24523058
[TBL] [Abstract][Full Text] [Related]
4. Nanobodies targeting immune checkpoint molecules for tumor immunotherapy and immunoimaging (Review).
Yu S; Xiong G; Zhao S; Tang Y; Tang H; Wang K; Liu H; Lan K; Bi X; Duan S
Int J Mol Med; 2021 Feb; 47(2):444-454. PubMed ID: 33416134
[TBL] [Abstract][Full Text] [Related]
5. Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics.
Naidoo DB; Chuturgoon AA
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575943
[TBL] [Abstract][Full Text] [Related]
6. Nanobody-based cancer therapy of solid tumors.
Kijanka M; Dorresteijn B; Oliveira S; van Bergen en Henegouwen PM
Nanomedicine (Lond); 2015 Jan; 10(1):161-74. PubMed ID: 25597775
[TBL] [Abstract][Full Text] [Related]
7. Theranostics and metabolotheranostics for precision medicine in oncology.
Bhujwalla ZM; Kakkad S; Chen Z; Jin J; Hapuarachchige S; Artemov D; Penet MF
J Magn Reson; 2018 Jun; 291():141-151. PubMed ID: 29705040
[TBL] [Abstract][Full Text] [Related]
8. INDI-integrated nanobody database for immunoinformatics.
Deszyński P; Młokosiewicz J; Volanakis A; Jaszczyszyn I; Castellana N; Bonissone S; Ganesan R; Krawczyk K
Nucleic Acids Res; 2022 Jan; 50(D1):D1273-D1281. PubMed ID: 34747487
[TBL] [Abstract][Full Text] [Related]
9. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology.
Gomes Marin JF; Nunes RF; Coutinho AM; Zaniboni EC; Costa LB; Barbosa FG; Queiroz MA; Cerri GG; Buchpiguel CA
Radiographics; 2020 Oct; 40(6):1715-1740. PubMed ID: 33001789
[TBL] [Abstract][Full Text] [Related]
10. Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment.
Wang J; Kang G; Yuan H; Cao X; Huang H; de Marco A
Front Immunol; 2021; 12():838082. PubMed ID: 35116045
[TBL] [Abstract][Full Text] [Related]
11. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
[TBL] [Abstract][Full Text] [Related]
12. Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.
D'Huyvetter M; Xavier C; Caveliers V; Lahoutte T; Muyldermans S; Devoogdt N
Expert Opin Drug Deliv; 2014 Dec; 11(12):1939-54. PubMed ID: 25035968
[TBL] [Abstract][Full Text] [Related]
13. A novel immuno-gold labeling protocol for nanobody-based detection of HER2 in breast cancer cells using immuno-electron microscopy.
Kijanka M; van Donselaar EG; Müller WH; Dorresteijn B; Popov-Čeleketić D; El Khattabi M; Verrips CT; van Bergen En Henegouwen PMP; Post JA
J Struct Biol; 2017 Jul; 199(1):1-11. PubMed ID: 28552722
[TBL] [Abstract][Full Text] [Related]
14. Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens.
Moradi A; Pourseif MM; Jafari B; Parvizpour S; Omidi Y
Pharmacol Res; 2020 Jun; 156():104790. PubMed ID: 32278043
[TBL] [Abstract][Full Text] [Related]
15. Versatile Nanosystem-Based Cancer Theranostics: Design Inspiration and Predetermined Routing.
Opoku-Damoah Y; Wang R; Zhou J; Ding Y
Theranostics; 2016; 6(7):986-1003. PubMed ID: 27217832
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?
Lütje S; Feldmann G; Essler M; Brossart P; Bundschuh RA
J Nucl Med; 2020 Aug; 61(8):1137-1144. PubMed ID: 31924724
[TBL] [Abstract][Full Text] [Related]
17. Nanobodies-Useful Tools for Allergy Treatment?
Flicker S; Zettl I; Tillib SV
Front Immunol; 2020; 11():576255. PubMed ID: 33117377
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle Diagnostics and Theranostics in the Clinic.
Pallares RM; Mottaghy FM; Schulz V; Kiessling F; Lammers T
J Nucl Med; 2022 Dec; 63(12):1802-1808. PubMed ID: 36302654
[TBL] [Abstract][Full Text] [Related]
19. Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials.
Paliard X; Rixe O
Target Oncol; 2019 Dec; 14(6):631-637. PubMed ID: 31595386
[TBL] [Abstract][Full Text] [Related]
20. Are nanotheranostics and nanodiagnostics-guided drug delivery stepping stones towards precision medicine?
Blau R; Krivitsky A; Epshtein Y; Satchi-Fainaro R
Drug Resist Updat; 2016 Jul; 27():39-58. PubMed ID: 27449597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
